Dose-finding Study With ACT-132577 (Aprocitentan) in Participants With Essential Hypertension

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1659 participants.

Also called NCT02603809

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 1,659 participants (enrolled count) (from the registry)
Sponsor
Idorsia Pharmaceuticals Ltd. (from the registry)
Registry
  • NCT NCT02603809
Other papers using this trial's data
  • Randomized Dose-Response Study of the New Dual Endothelin Receptor Antagonist Aprocitentan in Hypertension Hypertension (Dallas, Tex. : 1979), 2020-04 DOI, PubMed 32063059, PMC7098434 In the PMC Open Access subset under CC BY-NC-ND.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada, Israel, Puerto Rico (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02603809. Randomized; quadruple masking; primary purpose treatment. Start 2015-12-14 (actual); primary completion 2017-02-28 (actual). Results posted on 2020-04-13.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Dose-finding Study With ACT-132577 (Aprocitentan) in Participants With Essential Hypertension
Condition
Essential Hypertension
Intervention (Drug)
Aprocitentan 5 mg
Intervention (Drug)
Aprocitentan 10 mg
Intervention (Drug)
Aprocitentan 25 mg
Intervention (Drug)
Aprocitentan 50 mg
Intervention (Drug)
Lisinopril 20 mg
Intervention (Drug)
Placebo
Lead sponsor
Idorsia Pharmaceuticals Ltd. (class: industry)

Record details

Record id
cardio:ct-nct02603809
Content hash
82d46d8c385a45341d316e92b82fcdef0f4a407014fb836a15ca8c83197c1c37